IV Hydrogen Nanobubbles for Cardiac Function and QoL

NACompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 19, 2022

Primary Completion Date

November 4, 2022

Study Completion Date

November 4, 2022

Conditions
Cardiovascular DiseasesHypertensionBlood Pressure
Interventions
OTHER

intravenous infusion of hydrogen nanobubbles (HNB) administered twice weekly over a 5-week period

"This study investigated a novel intervention using intravenous hydrogen nanobubbles (HNBs), which are microscopic hydrogen gas bubbles encapsulated in liquid, offering enhanced stability, deep tissue penetration, and sustained antioxidant and anti-inflammatory effects. Unlike other hydrogen therapies (such as inhalation or hydrogen-rich water), this method delivers HNBs directly into the bloodstream.~Participants were randomized into six groups: one control group receiving saline and five intervention groups receiving escalating doses of HNBs (5-25 mL) over 10 intravenous infusions in 5 weeks. This intervention is distinct for its dose-response design, intravenous delivery, and combined evaluation of cardiovascular function and quality of life (SF-36)-a patient-centered approach not commonly found in similar studies."

Trial Locations (1)

65151

Indonesia Molecule Institute, Malang

All Listed Sponsors
lead

Indonesia Molecule Institute

NETWORK